Silke Lüschen

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 537 citations

Medicine, Hematology, Oncology +16

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Thorsten Raff, Nicola Gökbuget, Silke Lüschen et al. · Blood · 2006 · 238 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Sensitization to Death Receptor Cytotoxicity by Inhibition of Fas-associated Death Domain Protein (FADD)/Caspase Signaling

Silke Lüschen, Sandra Ussat, Gudrun Scherer et al. · Journal of Biological Chemistry · 2000 · 88 citations · Full text

Life Sciences, Cell Biology, Immunology +14

Caspase-Mediated Inhibition of Human Cytosolic Phospholipase A2 During Apoptosis

Sabine Adam‐Klages, Ralf Schwandner, Silke Lüschen et al. · The Journal of Immunology · 1998 · 67 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse

Vincent H. J. van der Velden, Monika Brüggemann, Patricia G. Hoogeveen et al. · Leukemia · 2004 · 66 citations

Life Sciences, Genetics, Molecular Biology +12